Back

Concomitant initiation of combination therapy with macitentan and tadalafil in pulmonary arterial hypertension (PAH) patients with comorbidities: Real-world data from OPUS and OrPHeUS

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Pulmonary hypertension around the real world Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Richard Channick

David Geffen School of Medicine at UCLA, Los Angeles (United States of America)

4 More presentations in this session

Presentation thumbnail
Pulmonary arterial hypertension associated with congenital heart disease: real-world analysis of clinical characteristics, treatment patterns and outcomes from EXPOSURE
Doctor M. Escribano Subias (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Characterisation of pulmonary arterial hypertension patients with cardiovascular comorbidities treated with selexipag: real-world evidence from the EXPOSURE study
Professor S. Soderberg (Umea, SE)
Abstract Slides Video
Presentation thumbnail
Incident pulmonary hypertension in 13,448 cases investigated with repeat echocardiography: insight from the national echo database of australia (NEDA)
Professor S. Stewart (Fremantle, AU)
Abstract Slides Video
Presentation thumbnail
Paediatric pulmonary arterial hypertension following congenital heart defect repair: enhanced risk stratification and outcomes in a national cohort
Doctor A. Constantine (Birmingham, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary hypertension around the real world

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
The importance of comorbidities in idiopathic and associated with connective tissue disease pulmonary arterial hypertension: from the Spanish Registry of Pulmonary Hypertension (REHAP Registry)
thumbnail
Congress Presentation
The role of age as a comorbidity in idiopathic and connective tissue disease-associated pulmonary arterial hypertension: from the Spanish Registry of Pulmonary Hypertension (REHAP Registry)
thumbnail
Congress Presentation
Use of parenteral prostanoids and outcomes in older patients with pulmonary arterial hypertension

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources